Advertisement

Journal of Clinical Immunology

, Volume 39, Issue 1, pp 112–117 | Cite as

Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma

  • Ludmila Perelygina
  • David Buchbinder
  • Morna J. Dorsey
  • Marc Eloit
  • Fabian Hauck
  • Timo Hautala
  • Despina Moshous
  • Ignacio Uriarte
  • Elena Deripapa
  • Joseph Icenogle
  • Kathleen E. SullivanEmail author
Original Article
  • 45 Downloads

Abstract

Purpose

Nitazoxanide was recently reported as having in vitro effectiveness against the rubella virus. Immunodeficiency-related vaccine-derived rubella occurs in some patients who have an inherited immunodeficiency and who received the MMR vaccine. This study investigated the in vivo effectiveness of nitazoxanide therapy.

Methods

This is a retrospective analysis of seven patients treated with nitazoxanide as salvage therapy for immunodeficiency-related vaccine-derived rubella infection. The patients were recruited from an ongoing rubella detection surveillance project.

Results

Seven patients with persistent rubella were treated with nitazoxanide and one demonstrated significant clinical improvement. Two additional patients exhibited diminished viral capsid production with one patient having transient slowing of progression. The cohort overall generally had low T cell counts and had a high burden of comorbidities. There were three deaths. Two deaths were from PML and one was related to hematopoietic stem cell transplantation.

Conclusions

Nitazoxanide has limited in vivo anti-viral effects for immunodeficiency-related vaccine-derived rubella. Most patients did not exhibit clinical improvement.

Keywords

Granulomas chronic inflammation vaccine nitazoxanide MMR 

Notes

Funding

This study was supported by the Wallace Chair of Pediatrics and the CDC.

Compliance with Ethical Standards

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, US Department of Health and Human Services.

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Tondury G, Smith DW. Fetal rubella pathology. J Pediatr. 1966;68:867–79.CrossRefGoogle Scholar
  2. 2.
    Fraser JR, Cunningham AL, Hayes K, Leach R, Lunt R. Rubella arthritis in adults. Isolation of virus, cytology and other aspects of the synovial reaction. Clin Exp Rheumatol. 1983;1:287–93.Google Scholar
  3. 3.
    Ferrini W, Aubert V, Balmer A, Munier FL, Abouzeid H. Anterior uveitis and cataract after rubella vaccination: a case report of a 12-month-old girl. Pediatrics. 2013;132:e1035–8.CrossRefGoogle Scholar
  4. 4.
    Abernathy E, Peairs RR, Chen MH, Icenogle J, Namdari H. Genomic characterization of a persistent rubella virus from a case of Fuch’ uveitis syndrome in a 73 year old man. J Clin Virol. 2015;69:104–9.CrossRefGoogle Scholar
  5. 5.
    Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, et al. Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect. 2014;20:O656–63.CrossRefGoogle Scholar
  6. 6.
    Perelygina L, Plotkin S, Russo P, Hautala T, Bonilla F, Ochs HD, et al. Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2016;138:1436–1439 e11.CrossRefGoogle Scholar
  7. 7.
    Privette ED, Ram G, Treat JR, Yan AC, Heimall JR. Healing of granulomatous skin changes in ataxia-telangiectasia after treatment with intravenous immunoglobulin and topical mometasone 0.1% ointment. Pediatr Dermatol. 2014;31:703–7.CrossRefGoogle Scholar
  8. 8.
    Dudgeon JA, Marshall WC, Peckham CS. Humoral immune responses in congenital rubella. Lancet. 1972;2:480–1.CrossRefGoogle Scholar
  9. 9.
    Perelygina L, Hautala T, Seppanen M, Adebayo A, Sullivan KE, Icenogle J. Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency. Antivir Res. 2017;147:58–66.CrossRefGoogle Scholar
  10. 10.
    Speckmann C, Doerken S, Aiuti A, Albert MH, Al-Herz W, Allende LM, et al. A prospective study on the natural history of patients with profound combined immunodeficiency: an interim analysis. J Allergy Clin Immunol. 2017;139:1302–1310 e4.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ludmila Perelygina
    • 1
  • David Buchbinder
    • 2
  • Morna J. Dorsey
    • 3
  • Marc Eloit
    • 4
  • Fabian Hauck
    • 5
  • Timo Hautala
    • 6
  • Despina Moshous
    • 7
    • 8
  • Ignacio Uriarte
    • 9
  • Elena Deripapa
    • 10
  • Joseph Icenogle
    • 1
  • Kathleen E. Sullivan
    • 11
    Email author
  1. 1.Division of Viral DiseasesCenters for Disease Control and PreventionAtlantaUSA
  2. 2.Division of HematologyCHOC Children’s HospitalOrangeUSA
  3. 3.Department of Pediatrics, Division of Allergy, Immunology, and Blood and Marrow Transplant, Benioff Children’s HospitalUniversity of CaliforniaSan FranciscoUSA
  4. 4.Institut Pasteur, Laboratory of Pathogen DiscoveryBiology of Infection UnitParisFrance
  5. 5.Department of Pediatrics, Dr. von Hauner Children’s HospitalUniversity HospitalMunichGermany
  6. 6.Research Unit of Internal MedicineUniversity of Oulu and Oulu University HospitalOuluFinland
  7. 7.Department of Pediatric Immunology, Hematology and Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP)Necker Children’s HospitalParisFrance
  8. 8.Laboratory “Genome Dynamics in The Immune System,” INSERM UMR1163Université Paris Descartes Sorbonne Paris Cité, Institut ImagineParisFrance
  9. 9.Immunology Unit, The Child’s and Mother Hospital, Vitorio Tetamanti, High School of MedicineMar del Plata National UniversityBuenos AiresArgentina
  10. 10.Department of ImmunologyCenter for Pediatric Hematology, Oncology, ImmunologyMoscowRussia
  11. 11.Division of Allergy Immunology, The Children’s Hospital of PhiladelphiaUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaUSA

Personalised recommendations